BerGenBio

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

Bergen, Norway, September 9, 2024- BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announcedtoday that the Company will participate in

the H.C. Wainwright 26th Annual Global Investment Conference held in New York

City, September 9-11, 2024.

Chief Executive Officer Martin Olin will provide a business update including the

ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung Cancer with STK11

mutations.

The presentation used at the conference is available in the investor section of

the Company's websitewww.bergenbio.com/investors/presentations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal